Previous 10 | Next 10 |
2023-12-06 13:16:08 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...
2023-12-03 12:00:30 ET More on SPDR S&P Biotech ETF Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biopharma Bounce-Back: From Policy Pains To Profitable Plains Biotechs rally with gene editing stocks among nota...
NORTHAMPTON, MA / ACCESSWIRE / December 1, 2023 / Nearly 36 years ago the AIDS Memorial Quilt was displayed for the first time to memorialize and physically represent lives lost to HIV. Gilead has always actively supported the Quilt, and creating a new panel made sense for a company dedicated to...
2023-11-30 16:55:30 ET Summary September-October, 2023, Barron’s, Bloomberg, and Fortune analysts and reporters combined to list five sets of stocks sorted as “Recovery Bets.” Those five articles revealed 53 equities, with 42 paying-dividends. These recovery l...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced it will present new data at San Antonio Breast Cancer Symposium (SABCS) 2023, supporting the use of Trodelvy ® (sacituzumab govitecan-hziy) in certain metastatic triple-negative breast cancer (mTNBC) and pre-treated HR+/HER2- metastati...
2023-11-29 15:00:01 ET Summary Biogen's latest Alzheimer's drug, Aduhelm, faced challenges after FDA approval, leading to concerns about efficacy and high costs. Biogen and Eisai's latest FDA-approved lecanemab faces similar risks; as a result, shares are down over 20% year-over-y...
2023-11-29 11:27:07 ET Gilead Sciences, Inc. (GILD) Piper Sandler 35th Annual Healthcare Conference November 29, 2023 9:00 AM ET Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Participants Joseph Catanzaro - Piper Sandler ...
2023-11-28 16:32:07 ET Gilead Sciences, Inc. (GILD) 6th Annual Evercore ISI HealthCONx Conference November 28, 2023 01:20 PM ET Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Participants Umer Raffat - Evercore ISI Prese...
2023-11-28 13:04:01 ET Summary Gilead's $21 billion 2020 acquisition of Immunomedics has generated growing revenues from Trodelvy, a first-in-class antibody-drug conjugate. Aggregate revenues from this deal have been modest though it has significant potential in the midterm future...
2023-11-28 10:52:22 ET The U.S. Food and Drug Administration (FDA) on Tuesday said it was looking into reports of T-cell malignancies in patients who have been treated with CAR-T cell immunotherapies directed towards the proteins BCMA and CD19. The regulator said it had determined that ...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2024 financial results and guidance will be released on Thursday, August 8, 2024, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’...
– New 5-Year Clinical and Real-World Data Reinforce Biktarvy ® as a Long-Term Treatment Option for a Diverse Range of People with HIV, Including Those with Comorbidities – – Investigational, Once-Daily, Once-Weekly and Twice-Yearly Dosing Frequenc...
– PURPOSE 1 Data Showed Zero Infections and 100% Efficacy and Superiority of Lenacapavir to Background HIV Incidence and Daily Truvada ® for PrEP – – If Approved, Lenacapavir Would be the First and Only Twice-Yearly PrEP Choice and Could Address C...